Novartis tender offer for MorphoSys commences
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The company will respond to the Warning Letter within the stipulated timelines
The company plans to add 1700 beds by FY27 through the organic route
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
New leadership team announced at NATHEALTH Annual General Meeting 2024
Subscribe To Our Newsletter & Stay Updated